Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular DegenerationTwelve-Week Results of an Uncontrolled Open-Label Clinical Study
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
669
total citations
- FWCI
- 68.33
- Percentile
- 100%
- References
- 70
Citations per year
Authors
5Topics & keywords
Topics
Keywords
- Medicine
- Macular degeneration
- Bevacizumab
- Choroidal neovascularization
- Fluorescein angiography
- Adverse effect
- Visual acuity
- Ophthalmology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.